These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 21324723

  • 1. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
    Chong Y, Yakushiji H, Ito Y, Kamimura T.
    Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
    [Abstract] [Full Text] [Related]

  • 2. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
    Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG.
    Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
    [Abstract] [Full Text] [Related]

  • 3. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
    Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR.
    Transpl Infect Dis; 2013 Apr; 15(2):142-9. PubMed ID: 23279656
    [Abstract] [Full Text] [Related]

  • 4. Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies.
    Chong Y, Yakushiji H, Ito Y, Kamimura T.
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e171-5. PubMed ID: 20471883
    [Abstract] [Full Text] [Related]

  • 5. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
    Ugarte-Torres A, Villasis-Keever A, Hernández-Bribiesca ME, Crespo-Solis E, Ruiz-Palacios GM, Sifuentes-Osornio J, Ponce-De-León-Garduño A.
    Rev Invest Clin; 2006 Sep; 58(6):547-54. PubMed ID: 17432285
    [Abstract] [Full Text] [Related]

  • 6. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
    Reuter S, Kern WV, Sigge A, Döhner H, Marre R, Kern P, von Baum H.
    Clin Infect Dis; 2005 Apr 15; 40(8):1087-93. PubMed ID: 15791505
    [Abstract] [Full Text] [Related]

  • 7. Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.
    Chee L, Brown M, Sasadeusz J, MacGregor L, Grigg AP.
    J Infect; 2008 Apr 15; 56(4):227-33. PubMed ID: 18342947
    [Abstract] [Full Text] [Related]

  • 8. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.
    Verlinden A, Jansens H, Goossens H, van de Velde AL, Schroyens WA, Berneman ZN, Gadisseur AP.
    Eur J Haematol; 2014 Oct 15; 93(4):302-8. PubMed ID: 24750350
    [Abstract] [Full Text] [Related]

  • 9. Moxifloxacin prophylaxis in neutropenic patients.
    von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Döhner H, Kern P, Reuter S.
    J Antimicrob Chemother; 2006 Oct 15; 58(4):891-4. PubMed ID: 16880172
    [Abstract] [Full Text] [Related]

  • 10. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.
    Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J.
    Clin Microbiol Infect; 2013 May 15; 19(5):474-9. PubMed ID: 22524597
    [Abstract] [Full Text] [Related]

  • 11. Bacteremia in patients with hematological malignancies.
    Wang FD, Lin ML, Liu CY.
    Chemotherapy; 2005 May 15; 51(2-3):147-53. PubMed ID: 15886475
    [Abstract] [Full Text] [Related]

  • 12. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis.
    Busca A, Cavecchia I, Locatelli F, D'Ardia S, De Rosa FG, Marmont F, Ciccone G, Baldi I, Serra R, Gaido E, Falda M.
    Transpl Infect Dis; 2012 Feb 15; 14(1):40-8. PubMed ID: 21599817
    [Abstract] [Full Text] [Related]

  • 13. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002.
    Kern WV, Steib-Bauert M, de With K, Reuter S, Bertz H, Frank U, von Baum H.
    J Antimicrob Chemother; 2005 Jan 15; 55(1):57-60. PubMed ID: 15574472
    [Abstract] [Full Text] [Related]

  • 14. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.
    Kara Ö, Zarakolu P, Aşçioğlu S, Etgül S, Uz B, Büyükaşik Y, Akova M.
    Infect Dis (Lond); 2015 Jan 15; 47(10):686-93. PubMed ID: 26024284
    [Abstract] [Full Text] [Related]

  • 15. [Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].
    Sinkó J, Cser V, Konkoly Thege M, Masszi T.
    Orv Hetil; 2011 Jul 03; 152(27):1063-7. PubMed ID: 21676672
    [Abstract] [Full Text] [Related]

  • 16. Emerging bacterial resistance patterns in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan.
    Khan MA, Siddiqui BK, Shamim A, Yosuf MA, Ahmed U, Zakiullah N, Burney IA.
    J Pak Med Assoc; 2004 Jul 03; 54(7):357-60. PubMed ID: 15449917
    [Abstract] [Full Text] [Related]

  • 17. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND, Gan GG, Adeeba K.
    Ann Hematol; 2008 Jul 03; 87(7):563-9. PubMed ID: 18437382
    [Abstract] [Full Text] [Related]

  • 18. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.
    Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G.
    J Antimicrob Chemother; 2008 Mar 03; 61(3):721-8. PubMed ID: 18218645
    [Abstract] [Full Text] [Related]

  • 19. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres.
    Castagnola E, Haupt R, Micozzi A, Caviglia I, Testi AM, Giona F, Parodi S, Girmenia C.
    Clin Microbiol Infect; 2005 Jun 03; 11(6):505-7. PubMed ID: 15882204
    [Abstract] [Full Text] [Related]

  • 20. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    Slobbe L, Waal Lv, Jongman LR, Lugtenburg PJ, Rijnders BJ.
    Eur J Cancer; 2009 Nov 03; 45(16):2810-7. PubMed ID: 19647995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.